<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical consequences of hemodialysis membrane biocompatibility</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical consequences of hemodialysis membrane biocompatibility</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical consequences of hemodialysis membrane biocompatibility</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steve J Schwab, MD, FACP, FASN</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 05, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Interaction of the dialysis membrane with the components of blood has the potential to induce an inflammatory response and to lead to numerous long-term clinical sequelae that are in part determined by the degree of membrane biocompatibility. A biocompatible membrane (BCM) has traditionally been defined as "one that elicits the least amount of inflammatory response in patients exposed to it" [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/1868.html" rel="external">"Biochemical mechanisms involved in blood-hemodialysis membrane interactions"</a>.)</p><p>However, there is no standard technique for the measurement of biocompatibility. As a result, there are wide-ranging claims for biocompatibility by manufacturers of dialysis membranes based upon the testing method utilized, such as the generation of leukotrienes or the degree of complement activation.</p><p>Issues related to the clinical consequences of hemodialysis membrane biocompatibility are discussed in this topic review. Acute reactions to the hemodialysis membrane, such as that induced by ethylene oxide and complement activation are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1859.html" rel="external">"Reactions to the hemodialysis membrane"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">TYPES OF HEMODIALYSIS MEMBRANES</span><span class="headingEndMark"> — </span>There are three types of membranes currently used to manufacture dialyzers: cellulose, substituted cellulose, and synthetic noncellulose.</p><p class="headingAnchor" id="H3"><span class="h2">Cellulose</span><span class="headingEndMark"> — </span>Cellulose, primarily manufactured as cuprophan (or cuprophane), is a polysaccharide-based membrane obtained from pressed cotton. It is composed of chains of glucosan rings with abundant free hydroxyl groups. Cupammonium is primarily used in the manufacturing process of this membrane (hence the name), but other methods of manufacturing exist.</p><p>These membranes, which are generally low flux, are best considered to be bioincompatible. However, reuse techniques that avoid bleach tend to greatly increase their biocompatibility due to the plating of plasma proteins across the membranes. (See  <a class="medical medical_review" href="/z/d/html/1863.html" rel="external">"Reuse of dialyzers"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Substituted cellulose</span><span class="headingEndMark"> — </span>Substituted cellulose membranes are obtained by chemical bonding or substitution of a material to the free hydroxyl groups at the surface of the cellulose polymer. The most common type is cellulose acetate, in which acetate replaces 80 percent of the hydroxyl groups. Such membranes can also be modified by the addition of a synthetic material (such as diethylaminoethyl in the production of Hemophane) to liquefied cellulose during its formation.</p><p>This class of membranes has a broad range of biocompatibility, ranging from relatively bioincompatible (as with cellulose acetate) to extremely biocompatible (as with cellulose triacetate). As with nonsubstituted cellulose membranes, improved biocompatibility is observed with reuse techniques that avoid bleach. The permeabilities of these membranes range from high to low flux.</p><p class="headingAnchor" id="H5"><span class="h2">Synthetic noncellulose</span><span class="headingEndMark"> — </span>Synthetic noncellulose membranes have a higher permeability and are more biocompatible than the cellulose membranes. There are a variety of synthetic membranes available including polyacrylonitrile (PAN), polysulfone, polycarbonate, polyamide, and polymethylmethacrylate (PMMA) membranes. They have permeabilities that range from low to high flux.</p><p class="headingAnchor" id="H6"><span class="h2">Determinants of biocompatibility</span><span class="headingEndMark"> — </span>The free hydroxyl groups on the cellulosic dialysis membrane activate the alternate pathway of complement, leading to neutrophil activation and subsequent sequestration in the pulmonary circulation and infiltration in other organs [<a href="#rid2">2,3</a>]. The side-group modifications on substituted cellulose membranes and the high adsorptive capacity of synthetic membranes generally lead to a decrease in the intensity of blood membrane interactions. As an example, the PAN membrane can vigorously activate the complement system; however, it also has a high adsorptive capacity for complement, resulting in a low net level of complement activation products reaching the systemic circulation. (See  <a class="medical medical_review" href="/z/d/html/1868.html" rel="external">"Biochemical mechanisms involved in blood-hemodialysis membrane interactions", section on 'Composition of dialysis membranes'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">ACUTE KIDNEY INJURY</span><span class="headingEndMark"> — </span>Studies in experimental animals with acute kidney injury (AKI) have shown that hemodialysis with cuprophane membranes (but not more compatible membranes) can lead to neutrophilic infiltration into the kidney (and other tissues) and delayed recovery from AKI.</p><p>These findings may also be applicable to humans as some prospective randomized trials have shown that the survival rate and the rate of recovery of critically ill patients from AKI were significantly higher and that recovery occurred earlier when hemodialysis was performed with biocompatible membranes (BCMs) rather than bioincompatible cuprophane membranes. Other studies, however, have failed to detect a difference in survival with these different membranes. (See  <a class="medical medical_review" href="/z/d/html/1938.html" rel="external">"Dialysis-related factors that may influence recovery of kidney function in acute kidney injury (acute renal failure)", section on 'Characteristics of the dialysis membrane'</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">CHRONIC KIDNEY DISEASE</span><span class="headingEndMark"> — </span>There are no prospective randomized studies suggesting that using biocompatible membranes (BCMs) for maintenance hemodialysis is associated with a lower morbidity and mortality when compared with dialysis with bioincompatible membranes (BICMs). However, several nonrandomized studies and post-hoc analyses support this possibility [<a href="#rid1">1,4-7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>One report, for example, compared the survival of patients who were switched from hemodialysis with a cellulosic membrane to hemodialysis with a high-flux polysulfone BCM [<a href="#rid4">4</a>]. Multivariate analysis, adjusted for all known comorbid conditions, showed that annual mortality was substantially less in patients treated with the polysulfone membrane (7 versus 20 percent). There was no difference in the overall rate of hospital admissions between the two groups, but infection-related admissions were twice as high in patients treated with the cellulosic membranes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A similar benefit was suggested in two reports from the United States Renal Data System (USRDS) case mix adequacy study, which compared the outcomes in patients dialyzed with cellulose or more compatible modified cellulose or synthetic membranes [<a href="#rid5">5,7</a>]. Compared with dialysis with cellulosic BICMs, the last two membranes were associated with an adjusted relative risk (RR) of overall mortality of 0.75 to 0.80 [<a href="#rid5">5</a>], as well as an adjusted RR of mortality due to coronary artery disease or infection of 0.74 and 0.69, respectively [<a href="#rid7">7</a>]. The relative roles of biocompatibility and higher flux in the apparent benefit could not be determined; furthermore, this type of study cannot prove a cause-and-effect relationship.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a post-hoc analysis of the 4D study, dialysis was performed with four different types of dialysis membranes: high-flux synthetic, low-flux synthetic, low-flux semisynthetic, or cellulosic low-flux membranes [<a href="#rid8">8</a>]. Compared with low-flux synthetic membranes (biocompatible), there was a significantly greater risk of death with low-flux cellulosic (hazard ratio [HR] 1.73, CI 95% 1.04-2.87) and low-flux semisynthetic membranes (HR 1.42, CI 95% 1.01-2.00).</p><p></p><p>In response in part to the data suggesting possible outcomes benefit (or at least no increased harm) with the use of BCMs, nephrologists in the United States have increased the use of modified cellulose or synthetic membranes [<a href="#rid1">1</a>]. It should be remembered, however, that simultaneous improvement in other features of dialysis treatment, such as increasing the delivered dose of dialysis, increasing the time on dialysis, or improving blood pressure control may mask or override adverse reactions to cellulosic membranes. (See  <a class="medical medical_review" href="/z/d/html/1847.html" rel="external">"Patient survival and maintenance dialysis"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">BETA-2 MICROGLOBULIN AND DIALYSIS-RELATED AMYLOIDOSIS</span><span class="headingEndMark"> — </span>Amyloidosis in patients on maintenance dialysis is related to the accumulation and tissue deposition of beta-2 microglobulin. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1983.html" rel="external">"Dialysis-related amyloidosis"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">PROTEIN CATABOLISM</span><span class="headingEndMark"> — </span>There is some evidence that the nutritional status of the hemodialysis patient can be influenced by the biocompatibility of the membrane [<a href="#rid9">9-11</a>]. In particular, the release of cytokines from cells activated after contact with bioincompatible membranes (BICMs) may be responsible for increased protein catabolism.</p><p>One report, for example, demonstrated net protein catabolism when normal subjects were exposed to (not dialyzed by) cellulosic membranes, but not when exposed to biocompatible (BCM) polysulfone or polyacrylonitrile (PAN) membranes [<a href="#rid12">12</a>]. A 150-minute exposure to the cuprophane membrane resulted in the net degradation of approximately 15 to 20 g of muscle protein (measured by the release of amino acids). The net release of amino acids occurred three hours after the end of dialysis, not during dialysis, and continued for as long as six and one-half hours after dialysis. This time course is similar to that of monocyte activation, the release of cytokines, and their subsequent action on muscle cells [<a href="#rid9">9</a>].</p><p>Two other observations reported a beneficial effect of BCMs on nutritional status:</p><p class="bulletIndent1"><span class="glyph">●</span>One study found that, for a given dose of dialysis, protein intake (reflected by the protein catabolic rate) increased to a greater extent in patients dialyzed with PAN membranes compared with those treated with cuprophane membranes [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A multicenter trial randomly assigned 159 patients newly initiated on dialysis to a BCM or BICM [<a href="#rid11">11</a>]. Patients treated with BCMs had higher plasma levels of albumin and insulin-like growth factor-1 and a greater degree of body-mass weight gain during the 18 months of the study.</p><p></p><p>However, large protein losses have also been reported among patients who are dialyzed with BCM [<a href="#rid13">13</a>]. </p><p class="headingAnchor" id="H11"><span class="h1">INFECTION</span><span class="headingEndMark"> — </span>Uremic patients have enhanced susceptibility to infection due in part to impaired neutrophil function [<a href="#rid14">14,15</a>]. Neutrophils eliminate bacteria through a series of carefully orchestrated events, including adherence to vascular endothelium, migration through the endothelium to the sites of infection, ingestion of bacteria, and killing the bacteria by the generation of reactive oxygen species and the release of microbial enzymes [<a href="#rid16">16</a>].</p><p>The hemodialysis membrane may play a role in this enhanced susceptibility to infection [<a href="#rid14">14,15,17-21</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>One retrospective study compared the major causes of mortality in approximately 1000 patients before and after their hemodialysis membranes were changed from cellulosic to a biocompatible polysulfone membrane [<a href="#rid22">22</a>]. The most significant difference in the cause of death between these two time periods was in the incidence of infection, which was decreased by approximately one-half during therapy with the polysulfone membrane. Similar results were noted in another report, in which the rate of hospitalization for infection in patients switched to a polysulfone membrane was one-half that in patients dialyzed with a cellulosic membrane [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neutrophils harvested predialysis from patients chronically dialyzed with cellulosic membranes have a significantly attenuated metabolic response to phagocytic stimuli such as latex or zymosan when compared with neutrophils from patients treated with a polysulfone membrane [<a href="#rid23">23</a>]. During a follow-up of approximately six months, there was a higher incidence of clinically apparent infections in patients dialyzed with a bioincompatible membrane (BICM).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum from patients dialyzed with BICMs may improve the adherence ability of hematopoietic cells. As an example, one study found that serum collected from patients being dialyzed with cuprophane hemodialysis membranes significantly increased the ability of granulocytes and monocytes to adhere to human saphenous vein endothelial cells [<a href="#rid24">24</a>]. This finding may be due to the presence of active complement fragments, which increase expression of neutrophil and monocyte adhesion receptors. No significant effect was observed with serum from patients undergoing dialysis with polysulfone hemodialysis membranes.</p><p></p><p>There is also evidence that lymphopenia and impaired natural killer cell (NKC) function occur in patients dialyzed with BICMs. Switching to a biocompatible membrane (BCM) can improve the lymphopenia [<a href="#rid25">25</a>] and NKC function [<a href="#rid19">19</a>]. NKCs can spontaneously lyse target cells without prior sensitization; they are important in providing resistance to viral infection and destroying tumor cells. The impairment in NKC function with cellulosic membranes may explain, in part, why hemodialysis patients have immune defects (such as a decreased responsiveness to vaccines) and an increased incidence of malignancy.</p><p class="headingAnchor" id="H12"><span class="h1">GENERAL INFLAMMATION</span><span class="headingEndMark"> — </span>The aggravation of general inflammatory processes in those undergoing maintenance hemodialysis may occur with exposure to dialysis tubing and dialysis membranes, particularly less biocompatible membranes. (See  <a class="medical medical_review" href="/z/d/html/1939.html" rel="external">"Inflammation in patients with kidney function impairment"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">LOSS OF RESIDUAL KIDNEY FUNCTION</span><span class="headingEndMark"> — </span>The initiation of hemodialysis is associated with a rapid decrease in residual kidney function at a rate that is approximately twice as fast as in patients starting peritoneal dialysis. There are conflicting data on the effect of biocompatible membranes (BCMs) compared with bioincompatible membranes (BICMs). (See  <a class="medical medical_review" href="/z/d/html/1941.html" rel="external">"Residual kidney function in kidney failure"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">PULMONARY CHANGES</span><span class="headingEndMark"> — </span>A large increase in the concentration of elastin fragments (most likely from lung parenchyma) is seen in patients dialyzed with cellulosic membranes. It has been suggested that patients chronically dialyzed with cellulosic membranes have increased release of elastase from activated neutrophils, resulting in breakdown of pulmonary elastin fibrils [<a href="#rid26">26</a>]. Reduced function of the inhibitory proteins of elastase in the presence of reactive oxygen species also may contribute to the rise in elastase activity. The clinical consequences of these changes are not known.</p><p>In addition to these chronic changes, sequestration of neutrophils in the lungs during cuprophane dialysis has been partially incriminated in the hypoxemia seen in the early phase of dialysis in association with concurrent leukopenia [<a href="#rid2">2,3,27</a>]. (See  <a class="medical medical_review" href="/z/d/html/1859.html" rel="external">"Reactions to the hemodialysis membrane", section on 'Type B reactions'</a>.)</p><p class="headingAnchor" id="H1379692576"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Interaction of the dialysis membrane with blood components may induce an inflammatory response with long-term clinical sequelae. The degree to which this occurs may in part be determined by membrane biocompatibility. A biocompatible membrane (BCM) is defined as one that elicits the least amount of inflammatory response. There is no standard technique for the measurement of biocompatibility. (See  <a class="medical medical_review" href="/z/d/html/1868.html" rel="external">"Biochemical mechanisms involved in blood-hemodialysis membrane interactions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are three types of membranes used to manufacture dialyzers: cellulose, substituted cellulose, and synthetic noncellulose. Cellulose membranes are best considered to be bioincompatible, although reuse techniques that avoid bleach increase their biocompatibility. Substituted cellulose membranes vary in the degree of biocompatibility, and, as with nonsubstituted cellulose membranes, biocompatibility is increased with reuse techniques. Synthetic noncellulose membranes are more biocompatible than the cellulose membranes. Available synthetic membranes include polyacrylonitrile (PAN), polysulfone, polycarbonate, polyamide, and polymethylmethacrylate (PMMA) membranes. (See <a class="local">'Types of hemodialysis membranes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemodialysis with cuprophane membranes (but not more compatible membranes) may lead to neutrophilic infiltration into the kidney (and other tissues) and delayed recovery from acute kidney injury. Some studies suggest that the use of BCMs is associated with a lower morbidity and mortality. As a result of these data, nephrologists in the United States have increased the use of modified cellulose or synthetic membranes. (See <a class="local">'Acute Kidney Injury'</a> above and <a class="local">'Chronic kidney disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The biocompatibility of the membrane may influence the accumulation of beta-2 microglobulin, nutritional status, susceptibility to infection, and the loss of residual kidney function. (See <a class="local">'Beta-2 microglobulin and dialysis-related amyloidosis'</a> above and <a class="local">'Protein catabolism'</a> above and <a class="local">'Infection'</a> above and <a class="local">'Loss of residual kidney function'</a> above and <a class="local">'Pulmonary changes'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Grooteman MP, Nubé MJ. Impact of the type of dialyser on the clinical outcome in chronic haemodialysis patients: does it really matter? Nephrol Dial Transplant 2004; 19:2965.</a></li><li><a class="nounderline abstract_t">Craddock PR, Fehr J, Dalmasso AP, et al. Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 1977; 59:879.</a></li><li><a class="nounderline abstract_t">Hakim RM, Breillatt J, Lazarus JM, Port FK. Complement activation and hypersensitivity reactions to dialysis membranes. N Engl J Med 1984; 311:878.</a></li><li><a class="nounderline abstract_t">Hornberger JC, Chernew M, Petersen J, Garber AM. A multivariate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol 1992; 3:1227.</a></li><li><a class="nounderline abstract_t">Hakim RM, Held PJ, Stannard DC, et al. Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int 1996; 50:566.</a></li><li><a class="nounderline abstract_t">Koda Y, Nishi S, Miyazaki S, et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997; 52:1096.</a></li><li><a class="nounderline abstract_t">Bloembergen WE, Hakim RM, Stannard DC, et al. Relationship of dialysis membrane and cause-specific mortality. Am J Kidney Dis 1999; 33:1.</a></li><li><a class="nounderline abstract_t">Krane V, Krieter DH, Olschewski M, et al. Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. Am J Kidney Dis 2007; 49:267.</a></li><li><a class="nounderline abstract_t">Gutierrez A, Alvestrand A, Wahren J, Bergström J. Effect of in vivo contact between blood and dialysis membranes on protein catabolism in humans. Kidney Int 1990; 38:487.</a></li><li><a class="nounderline abstract_t">Lindsay RM, Spanner E, Heidenheim P, et al. PCR, Kt/V and membrane. Kidney Int Suppl 1993; 41:S268.</a></li><li><a class="nounderline abstract_t">Parker TF 3rd, Wingard RL, Husni L, et al. Effect of the membrane biocompatibility on nutritional parameters in chronic hemodialysis patients. Kidney Int 1996; 49:551.</a></li><li><a class="nounderline abstract_t">van Ypersele de Strihou C, Jadoul M, Malghem J, et al. Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. Kidney Int 1991; 39:1012.</a></li><li><a class="nounderline abstract_t">Murtas S, Aquilani R, Iadarola P, et al. Differences and Effects of Metabolic Fate of Individual Amino Acid Loss in High-Efficiency Hemodialysis and Hemodiafiltration. J Ren Nutr 2020; 30:440.</a></li><li><a class="nounderline abstract_t">Vanholder R, Ringoir S. Polymorphonuclear cell function and infection in dialysis. Kidney Int Suppl 1992; 38:S91.</a></li><li><a class="nounderline abstract_t">Vanholder R, Ringoir S. Infectious morbidity and defects of phagocytic function in end-stage renal disease: a review. J Am Soc Nephrol 1993; 3:1541.</a></li><li><a class="nounderline abstract_t">Grooteman MP, Nubé MJ. Haemodialysis-related bioincompatibility: fundamental aspects and clinical relevance. Neth J Med 1998; 52:169.</a></li><li><a class="nounderline abstract_t">Himmelfarb J, Zaoui P, Hakim R. Modulation of granulocyte LAM-1 and MAC-1 during dialysis--a prospective, randomized controlled trial. Kidney Int 1992; 41:388.</a></li><li><a class="nounderline abstract_t">Zaoui P, Green W, Hakim RM. Hemodialysis with cuprophane membrane modulates interleukin-2 receptor expression. Kidney Int 1991; 39:1020.</a></li><li><a class="nounderline abstract_t">Zaoui P, Hakim RM. Natural killer-cell function in hemodialysis patients: effect of the dialysis membrane. Kidney Int 1993; 43:1298.</a></li><li><a class="nounderline abstract_t">Himmelfarb J, Lazarus JM, Hakim R. Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis. Am J Kidney Dis 1991; 17:271.</a></li><li><a class="nounderline abstract_t">Vanholder R, Smet RD, Glorieux G, Dhondt A. Survival of hemodialysis patients and uremic toxin removal. Artif Organs 2003; 27:218.</a></li><li><a class="nounderline abstract_t">Levin NW, Zasuwa GA, Dumler F. Effect of membrane types on causes of death in hemodialysis patients (abstract). J Am Soc Nephrol 1991; 2:335.</a></li><li><a class="nounderline abstract_t">Vanholder R, Ringoir S, Dhondt A, Hakim R. Phagocytosis in uremic and hemodialysis patients: a prospective and cross sectional study. Kidney Int 1991; 39:320.</a></li><li><a class="nounderline abstract_t">Thylén P, Fernvik E, Haegerstrand A, et al. Dialysis-induced serum factors inhibit adherence of monocytes and granulocytes to adult human endothelial cells. Am J Kidney Dis 1997; 29:78.</a></li><li><a class="nounderline abstract_t">Degiannis D, Czarnecki M, Donati D, et al. Normal T lymphocyte function in patients with end-stage renal disease hemodialyzed with 'high-flux' polysulfone membranes. Am J Nephrol 1990; 10:276.</a></li><li><a class="nounderline abstract_t">Hakim RM. Clinical implications of hemodialysis membrane biocompatibility. Kidney Int 1993; 44:484.</a></li><li><a class="nounderline abstract_t">Hakim RM, Lowrie EG. The relative effect of leukopenia and dialysate composition on the dialysis-associated hypoxemia. Proc Clin Dial Transplant Forum 1980; 10:190.</a></li></ol></div><div id="topicVersionRevision">Topic 1873 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15507481" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Impact of the type of dialyser on the clinical outcome in chronic haemodialysis patients: does it really matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/856872" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6332276" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Complement activation and hypersensitivity reactions to dialysis membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1477318" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A multivariate analysis of mortality and hospital admissions with high-flux dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8840287" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effect of the dialysis membrane on mortality of chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9328951" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9915261" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Relationship of dialysis membrane and cause-specific mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17261429" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2232492" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effect of in vivo contact between blood and dialysis membranes on protein catabolism in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8320934" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : PCR, Kt/V and membrane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8821843" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effect of the membrane biocompatibility on nutritional parameters in chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2067196" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32303413" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Differences and Effects of Metabolic Fate of Individual Amino Acid Loss in High-Efficiency Hemodialysis and Hemodiafiltration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1405386" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Polymorphonuclear cell function and infection in dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8507809" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Infectious morbidity and defects of phagocytic function in end-stage renal disease: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9652155" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Haemodialysis-related bioincompatibility: fundamental aspects and clinical relevance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1372668" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Modulation of granulocyte LAM-1 and MAC-1 during dialysis--a prospective, randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2067197" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hemodialysis with cuprophane membrane modulates interleukin-2 receptor expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8315942" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Natural killer-cell function in hemodialysis patients: effect of the dialysis membrane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1996568" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12662205" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Survival of hemodialysis patients and uremic toxin removal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effect of membrane types on causes of death in hemodialysis patients (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2002645" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Phagocytosis in uremic and hemodialysis patients: a prospective and cross sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9002533" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Dialysis-induced serum factors inhibit adherence of monocytes and granulocytes to adult human endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2240054" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Normal T lymphocyte function in patients with end-stage renal disease hemodialyzed with 'high-flux' polysulfone membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8231020" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical implications of hemodialysis membrane biocompatibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6810343" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The relative effect of leukopenia and dialysate composition on the dialysis-associated hypoxemia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
